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BACKGROUND: Metabolic changes in tumour cells are used in clinical imaging and may provide potential therapeutic targets.
Human papillomavirus (HPV) status is important in classifying head and neck cancers (HNSCC), identifying a distinct clinical
phenotype; metabolic differences between these HNSCC subtypes remain poorly understood.
METHODS: We used RNA sequencing to classify the metabolic expression profiles of HPV+ve and HPV−ve HNSCC, performed a
meta-analysis on FDG-PET imaging characteristics and correlated results with in vitro extracellular flux analysis of HPV−ve and
HPV+ve HNSCC cell lines. The monocarboxylic acid transporter-1 (MCT1) was identified as a potential metabolic target and tested in
functional assays.
RESULTS: Specific metabolic profiles were associated with HPV status, not limited to carbohydrate metabolism. There was
dominance of all energy pathways in HPV-negative disease, with elevated expression of genes associated with glycolysis and
oxidative phosphorylation. In vitro analysis confirmed comparative increased rates of oxidative phosphorylation and glycolysis in
HPV-negative cell lines. PET SUV(max) scores however were unable to reliably differentiate between HPV-positive and HPV-negative
tumours. MCT1 expression was significantly increased in HPV-negative tumours, and inhibition suppressed tumour cell invasion,
colony formation and promoted radiosensitivity.
CONCLUSION: HPV-positive and negative HNSCC have different metabolic profiles which may have potential therapeutic
applications.
British Journal of Cancer (2019) 120:356–367; https://doi.org/10.1038/s41416-018-0364-7
INTRODUCTION
The identification of common links between oncogenes and
important regulators of metabolism has fuelled a resurgent
interest in cancer cell metabolism, despite the Warburg effect
being first described nearly a century ago.1 This observation, that
cancer cells preferentially metabolise glucose even in the
presence of abundant oxygen, underpins the common clinical
use of positron emission tomography (PET) in clinical oncology;
this imaging modality uses a glucose analogue, fluorine-18-
fluorodeoxyglucose, to identify tissue with rapid glucose uptake.
Aerobic glycolysis is an inefficient pathway for generating ATP, but
is thought to confer a growth advantage for tumour cells,
providing a biosynthetic advantage by generating carbon
precursors required for the synthesis of macromolecules essential
for cell division.2,3 While aerobic glycolysis has become a
recognised ‘hallmark of malignancy’, its causal relationship to
tumourigenesis remains unclear.
Head and neck squamous cell carcinoma (HNSCC) is currently
classified into human papillomavirus-negative (HPV−ve) and
-positive (HPV+ve) disease. HPV+ve tumours are most commonly
found in the oropharynx (OPSCC), including the tonsil/base of
tongue region, with HPV status usually determined by expression
of a surrogate marker p16 (INK4A).4,5 HPV+ve and HPV−ve tumours
have significantly different molecular profiles and clinical beha-
viour, particularly with respect to invasion, metastasis and
response to chemoradiotherapy.6–8 PET imaging is routinely used
for identification, staging and follow up of HNSCC, however no
studies have examined how HPV status affects the metabolic
phenotypes of these tumours, which may in turn affect the clinical
ability to detect tumours. There is also increasing evidence of
fundamental links between a tumour’s metabolic phenotype, its
interactions with the tumour microenvironment and clinical
outcome,9–12 suggesting that specific metabolic pathways may
promote tumour progression and represent therapeutic targets.
Understanding the metabolic profiles of HNSCC cancer subtypes
may therefore impact on the clinical management of this disease.
MATERIALS AND METHODS
Cell lines, culture and treatment
HNSCC-derived HPV−ve cell lines SCC-2511 and UM-SCC8912 were
cultured in standard medium consisting of Dulbecco’s modified
Eagle’s medium (DMEM; Sigma Aldrich):Ham’s F12 (1:1; BioWhit-
taker), containing 10% (v/v) foetal bovine serum (FBS) and 2mM
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L-glutamine. Two immortalised cell lines derived from the upper
aerodigestive tract from suspected HPV+ve tumours, UD-SCC-2
and UPCI:SCC90,13,14 were kindly supplied by Susanne M. Gollin
(University of Pittsburgh, USA; shortened to SCC2 and SCC90
respectively in results). These cell lines, along with Detroit 562, an
additional HNSCC cell line used in functional analyses, were
cultured in 10% FBS supplemented DMEM. Polymerase chain
reaction (PCR) was performed to confirm the HPV status of cell
lines used in functional assays by the presence of E6/E7
oncoprotein RNA (Supplementary Figure 1). PCR was also utilised
to perform testing for mycoplasma throughout experimentation.
Cell counting for all functional assays was performed utilising a
CASY counter (Innovatis AG, UK/Roche Diagnostics GMBH).
AZD3965 (AstraZeneca, Waltham, MA) was reconstituted accord-
ing to the manufacturer’s instructions to a working stock
concentration of single use aliquots at 1 uM solution in DMSO.
Recent publications15 and a kill curve for the compound on SCC-
25 cells determined 10 nM inhibitor concentration as the
functional dose for functional analysis (Supplementary Figure 2);
cells were exposed to AZD3965 for 48 h prior to use in assays
unless otherwise stated.
Measurement of oxygen consumption rate (OCR) and extracellular
acidification rates (ECAR)
OCR and ECAR measurements were performed using the XF96
Extracellular Flux analyzer (Seahorse Bioscience, North Billerica,
MA) as described in Wu et al.16 Briefly, cells (2 × 104/well) were
plated in 80 µl of growth medium in a XF96 culture plate well,
while the probes were immersed in XF Calibrant Solution
(Seahorse Bioscience; lacking sodium bicarbonate and FCS)
overnight at 37 °C in non-CO2 incubator 24 h prior to experimental
run. Running medium for the assay was prepared using glucose-
free DMEM supplemented with 10% serum, 2 mM L-glutamine
(PAA) and 1mM sodium pyruvate (PAA), and the pH was adjusted
to 7.4 at 37 °C. Prior to performing the assay, drugs from
mitochondrial and glycolysis stress kits (Seahorse Bioscience)
were diluted in running medium and loaded into injection ports of
the probe cartridge. Cells were washed twice with 200 µl of
running medium, and the plate was placed in a non-CO2 37 °C
incubator whilst sensor cartridges were calibrated. OCR and ECAR
were measured over a 2-minute period as absolute rates (pmoles/
min and mpH/min respectively), followed by 3-min mixing and re-
oxygenation of the media. Experimental conditions in each assay
were performed with a minimum of triplicate wells. Glycolytic
capacity was calculated using the equation: maximum rate
measurement after oligomycin injection—last rate measurement
before glucose injection, expressed as mpH/min. A standard
Bradford assay (Bio-Rad Laboratories) analysis was performed on
end-point wells to normalise to total protein count per well (ug/
well).
Western blot analysis
Cells were lysed in NP40 buffer (Biosource, Invitrogen, Paisley, UK).
Samples containing equal amounts of protein were electrophor-
esed under reducing conditions in 8–10% SDS-PAGE gels. Protein
was electroblotted to PVDF membranes (Amersham Biosciences,
Buckinghamshire, UK). Blots were probed with antibodies against
MCT1 (Santa Cruz Biotechnology). Horseradish peroxidase-
conjugated anti-rat or anti-mouse (Dako) was used as secondary
antibodies. Bound antibodies were detected with the enhanced
chemiluminescence western blotting detection kit system (Amer-
sham). Blots were probed for Total FAK (Millipore) as a loading
control.
Invasion assay
Cell invasion was analysed using Transwell® assays (8 μm pore
size, polycarbonate membrane, Corning® Costar® Wiesbaden,
Germany) as previously described.17 Briefly, a layer of Matrigel
(BD Biosciences, San Diego, CA, USA) diluted 1:2 with DMEM was
placed on top of each insert prior to seeding 5 × 105 cells/200 µl in
each chamber. A 72-h incubation at 37 °C was performed to allow
invasion of cells to the lower chamber and counted using a CASY
counter (Innovatis AG, UK/Roche Diagnostics GMBH).
Organotypic culture
Organotypic cultures were prepared as previously described.17 A
1ml mixture comprising 3.5 volumes type I rat tail collagen (Merck
Millipore), 3.5 volumes Matrigel (Becton-Dickinson), 1 volume 10x
DMEM, 1 volume foetal calf serum and 1 volume of 10% DMEM
together with 2.5 × 105/ml HFFF2 cells was allowed to polymerise.
A mixture of HNSCC cells (5 × 105) and HFFF2 fibroblasts (25 × 104)
in a combined volume of 1ml of DMEM was then added dropwise
onto the top of the gel. After 24 h incubation, the gels were raised
onto nylon sheet coated stainless steel grids. After 7 days
incubation at 37 °C the gels were bisected, fixed in formal-saline
and processed to paraffin. Sections (4 μm) were stained for H&E ±
pan-cytokeratin.
Clonogenic survival assay
SCC-25 cells were treated with 10 nM AZD3965 or a DMSO control
for 48 h prior to the start of the survival assay, trypsinised, counted
and seeded in 6-well plates at 2000 cells/well. AZD3965/DMSO
containing media was replaced after 24 h and then left in situ for
10 days until conclusion of the experiment.
To test radiosensitivity, the cell suspensions were exposed to a
range of γ-ray doses in 2-Gy increments dose of γ-rays prior to
plating at 2000 cells/well. Standard cell media was utilised for both
control and AZD3965 pre-treated populations to homogenise post
radiation exposure conditions.
At completion cells were fixed in a 3% crystal violet/10%
formalin solution. Following collation of scanned images, the
‘ColonyArea’ plugin of Image J18 was utilised, allowing automated
thresholding and analysis, to calculate both % area and intensity
of colonies.
RNA sequencing and data analysis
Single ended 35 bp read length RNA-Seq was performed with
mRNA from 39 consecutively collected HNSCC tumour samples as
described in Wood et al.19 (data available in Gene Expression
Omnibus, accession number GSE72536). At the time of the present
study, 35 patients in this cohort initially had sequencing data
available for analysis. The quality of raw SE read data was assessed
and reads of low quality were removed using PRINSEQ and reads
with low complexity were remove using DUST, complexity scores
above 7 were removed. SE reads were then mapped to the human
genome (hg19) using TopHat (version 2.0.9) allowing no
mismatches. Only reads uniquely aligned were considered for
further counting using HTSeq-count (version 0.5.4), yielding read
count values for a total of 23,368 RefSeq annotated genes. The raw
counts were further processed in Bioconductor package EdgeR
(version 3.4.2). Nonspecific filtering of count data was performed
such that genes with less than 2 read counts per million in 25% of
the samples were removed. The remaining 14565 genes
(Supplementary Table 1A) were subject to normalisation using
the trimmed mean of M-values (TMM) normalisation method to
account for differences in library size between samples. The TMM
normalised data was subject to differentially expressed gene
(DEG) analysis using generalised linear model likelihood ratio test.
A gene was considered significantly differentially expressed when
the FDR adjusted, using Benjamini and Hochberg method, p-value
was lower than 0.05 and absolute fold change greater than 2. To
examine metabolism related genes, we collected ID codes for all
metabolism-related sub-pathways from the KEGG PATHWAY
database.20 MetabolicMine21 was then utilised to perform a query
for all genes involved in the identified pathways. Non-human
species results were excluded, and all gene symbols converted
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Fig. 1 Analysis of RNA sequencing data from HPV+ve (n= 11) and HPV−ve (n= 24) HNSCC. a Unsupervised Clustering of 1205 metabolism-
related genes with a Principal Component Analysis (PCA plot). b Genes involved in global metabolism pathways were extracted from KEGG
and their expression correlated with the differentially expressed genes (DEG) in HPV−ve and HPV+ve tumours to produce a heatmap of 111
genes. c Gene ontology analysis of 111 common metabolism-related genes differentially expressed between HPV+ve and HPV−ve HNSCC.
Analysis was performed in ToppGene and summarised as a scatterplot of cluster representative terms in REVIGO based on semantic similarity.
Bubble colour indicates the user-provided p-value and bubble size indicates the frequency of the GO term in the underlying database
(general terms produce larger bubbles). Clusters with the largest and most significant values have been highlighted with text descriptions
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into ensemble IDs (Supplementary Table 2). All genes were
matched to related IDs (3 genes lost in cross conversion (GALNTL2,
GALNTL4, PTPLA)). The DEG results were then correlated with the
metabolism related gene database.
Gene ontology (GO) and pathway analysis
GO terms associated with biological processes and biological
pathways that were significantly over-represented for DEGs (q-
value < 0.05) were identified with ToppGene web tool22 and
functional enrichment analysis was performed using ToppFun
from the ToppGene suite. Statistical significance of different GO
terms and pathways were estimated using hypergeometric testing
with FDR adjustment for multiple testing using the Benjamini and
Hochberg method. GO terms and functional pathways with FDR
corrected p-value < 0.05 was considered significant. Significant GO
terms were visualised in semantic similarity-based scatterplots
generated by REVIGO.
TMA production and immunohistochemistry
Immunohistochemical analysis was performed on a tissue micro-
array of consecutively-treated patients with oropharyngeal
squamous cell carcinoma (OPSCC; n= 260 (231 with confirmed
HPV status)) from University Hospital Southampton (2000-10),
Poole NHS Foundation (2000-6) and Bart’s and the London NHS
Trust (2000-6) as described previously23 (REC references 09/
H0501/90 and 07/Q0405/1). Tumours classified as HPV+ve were
positive for both p16 immunohistochemistry and HPV ISH.
Immunochemistry was performed using MCT1 antibody (Santa
Cruz Biotechnology) and scored by two blinded investigators (KM/
JF) as high (moderate/high strength staining) or low (absent/low
strength staining).
Systematic review
The following broad search strategy was utilised on Pubmed/
Medline and Embase: ((FDG OR PET) AND (HPV OR papilloma-
virus)), with all fields included and including dates 1946-present.
Titles and abstracts were scrutinised and full texts of relevant and
related articles were retrieved to enable final selection. Only cases
reporting SUV(max) scores were included. Case reports and
commentaries were excluded. Only English language articles
analysing the direct comparison between FDG-PET results in
HPV+ve and HPV−ve HNSCC were included. Studies only evaluating
other tumour types or without differentiation between viral and
non-virally derived HNSCC were excluded. Reference lists of key
articles were cross-referenced to identify additional articles. Where
mean SUV(max) was not reported, indicated mean values were
estimated from reported median, range and sample size.24 A
mean difference approach was used for meta-analysis and a
Forrest plot to examine effect created using Review Manager
version 5.0 (RevMan).25
Statistical analysis
For comparisons between experimental groups in functional
assays, a Student’s T-test was used. For other datasets where
normal distribution was not evident, non-parametric data analysis
was performed (Mann–Whitney test for unpaired, Wilcoxen
matched-pairs signed rank test; Prism v6 for Mac, Graphpad
Software). Error bars show standard deviation (SD) unless
otherwise stated. For TMA/database analysis, SPSS Statistics (v22
for Mac, IBM, NY) was used.
The primary endpoint for survival analysis was death from
OPSCC (i.e., disease-specific survival). An OPSCC-specific survival
time was measured from the date of diagnosis until date of death
from OPSCC or date last seen alive. Kaplan–Meier survival curves
were produced using clinicopathological patient data. Death from
other causes or loss to follow up was marked as censored for
analysis.
For all analyses, a p value of equal or less than 0.05 was
considered to be significant.
RESULTS
Transcriptional landscape of HNSCC cell metabolism
Current understanding of the relationship between HPV status
and HNSCC metabolism is limited. 35 HNSCC tumours (11 HPV+ve,
24 HPV−ve) were analysed by RNA sequencing19 to produce a
differentially expressed gene (DEG) list of 1587 genes based on
viral status (Supplementary Table 1B). We correlated this list with a
publicly available KEGG gene database of metabolism-related
genes, and then performed unsupervised clustering analysis on
this metabolism dataset using principal component analyses; this
separated the tumour subgroups according to HPV status (Fig. 1a),
confirmed on t-Distributed Stochastic Neighbour Embedding
(Supplementary Figure 3). 111 metabolism-related genes were
identified amongst the DEG between HPV+ve and HPV−ve tumours
(Fig. 1b); DEGs by cluster are listed in Supplementary Figure 4.
To identify differences in specific metabolic pathways between
HPV+ve and HPV−ve tumours, we performed gene ontology (GO)
analysis on the 111 differentially expressed, metabolism-related
genes and summarised results in REVIGO26 (Fig. 1c). The top GO
terms that highlighted differences between HPV+ve and HPV−ve
tumours included significant alterations in gene expression
(identifying both upregulated and downregulated genes) asso-
ciated with nucleotide biosynthesis and carbohydrate metabolism.
Metabolic enzyme expression analysis
Since gene ontology analysis revealed HPV-related differences in
carbohydrate metabolism (Fig. 1c), we next examined glycolysis
and related pathways in more detail, focusing on gene expression
of eight key enzymes (Fig. 2). Four enzymes from glycolysis were
included: hexokinase (HK1), phosphoglucose isomerase (PGI),
phosphofructokinase (PFKM), pyruvate kinase (PKM2, the major
isoform in tumours) and lactate dehydrogenase (LDHA). Other
enzymes included glucose-6-phosphate dehydrogenase (G6PD)
from the pentose phosphate pathway, pyruvate dehydrogenase
(PDHA1) and its kinase (PDK1) controlling entry into the TCA cycle.
This was supplemented by analysis of additional genes associated
with the pentose phosphate pathway (Supplementary Figure 5a)
and glucose metabolism (Supplementary Figure 5b).27 We found
that there was upregulation of glycolysis genes (HK1, PFKM, PKM2,
LDHA significantly upregulated) in HPV−ve HNSCC, which also
expressed lower levels of the negative regulator, PDK1 (Fig. 2).
Differences in the pentose phosphate pathway were less clear;
while expression of G6PD was upregulated in HPV−ve tumours,
other pentose pathway genes were not differentially expressed
(Supplementary Figure 5a). Analysis of the DEG list in the cellular
protein domain also revealed significant enrichment of mitochon-
drial matrix proteins (p= 6.962 × 10−6; Supplementary Figure 6).
These data suggest a more globally metabolically active signature
in HPV−ve tumours.
Real time extracellular flux analysis of HNSCC cell lines
To corroborate in vivo findings, we next examined the metabolic
phenotype of HNSCC cells in vitro, focussing specifically on
glycolysis and oxidative phosphorylation (OXPHOS). Four HNSCC
cell lines, two HPV−ve (SCC-25, UM-SCC-89) and two HPV+ve (UD-
SCC-2, UPCI:SCC90) were analysed using a Seahorse XF96
Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica,
MA) (Fig. 3), measuring oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR), which were used to
extrapolate cell mitochondrial respiratory function and glycolytic
function respectively. The HPV−ve cell lines had significantly
higher basal ECAR and OCR compared to the HPV+ve cell lines (p <
0.0001; Fig. 3a). The difference between maximal and basal ECAR
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is considered the glycolytic reserve capacity of cells; this revealed
that HPV−ve cells have potential for much higher glycolytic rates
than HPV+ve cells (Fig. 3b, left panel). The OCR/ECAR ratio showed
that UD-SCC-2 and UPCI:SCC90 were more reliant on mitochon-
drial respiration for their energy requirements (Fig. 3b, right
panel). Notably, despite their increased reliance on glycolysis, the
respiratory capacity of SCC-25 and UM-SCC-89 was also greater
than the HPV+ve lines, indicating a greater potential for ATP
production and theoretically allowing cells to switch between
OXPHOS and glycolysis to satisfy greater bioenergy demands
depending on various tumour-related factors such as blood
supply, hypoxia and the surrounding microenvironment. Both
HPV+ve cell lines appeared to be operating closer to their maximal
respiratory capacity under standard cell culture conditions.
Correlation of glycolytic phenotype with FDG PET imaging
The distinct in vivo and in vitro metabolic profiles between HPV+ve
and HPV−ve HNSCC prompted us to investigate whether these
differences were apparent on FDG-PET imaging. Prior research has
been limited by HPV−ve sample size due to the emerging
dominance of HPV+ve tumours in the oropharynx, and the
previous relatively confined use of PET imaging to this anatomical
site. We therefore performed a systematic review of the literature
and produced a virtual data-series from several comparative
studies, for analysis using SUV(max), which has been previously
proposed as the most accurate and reproducible SUV measure.28
We identified a total of 305 studies; following de-duplication,
243 studies were screened by title ± abstract. 229 were excluded
following initial screening. Full articles for the remaining 14 papers
were reviewed and from this, 7 studies were excluded due to not
fitting study aims (4) or insufficient data (3) (Supplementary
Figure 7). The data from the remaining 7 studies were combined
with our own database from two tertiary centres (N= 26; Age
range 42–87 years; Fig. 4a). Our results indicated a mean SUV(max)
score of 11.7 in the HPV−ve cohort (n= 7, SD= 9.59) and 11.3 in
the HPV+ve (n= 19, SD= 7.36). A meta-analysis was performed on
collated results, utilising a mean difference approach (Fig. 4b).
Summary statistics showed there to be moderate heterogeneity
between studies (I2 statistic= 0.42), with no overall difference
between SUV(max) scores based on HPV status, although there
was a strong trend for higher SUV(max) scores in the HPV−ve
populations (Z statistic= 1.71 (p= 0.09; mean difference= 1.22
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(95% CI −0.18–2.62). Although the trend for higher SUV(max)
scores in HPV−ve tumours is consistent with our in vitro findings,
the result suggests that, at a single timepoint, SUV(max) does not
accurately distinguish between HPV+ve and HPV-ve HNSCC.
Application of metabolic analysis to identify a new therapeutic
target
The distinct metabolic profiles of HPV+ve and HPV−ve HNSCC
raises the possibility that these differences may play a role in the
differing patient survival and response to therapy in these tumour
subgroups, as well as offering potential therapeutic targets. For
example, in glycolytically-active HPV−ve HNSCC cells, lactate
homoeostasis is likely to play a significant role in cell survival, a
process requiring specialised monocarboxylic acid transporters:
MCT1-4.29,30 Although these transporters facilitate metabolic
shuttles, they were not included in the public global metabolism
related gene list used for earlier comparison (Supplementary
table 2) and we therefore directly examined the RNA sequencing
data for expression of MCT1, MCT2 and MCT4 (MCT3 was not
included due to its restricted expression to retina/choroid plexus
epithelium). MCT2 (SLC16A7, p= 0.565) and MCT4 (SLC16A3, p=
0.438) showed no differential expression between HPV−ve and
HPV+ve HNSCC; MCT1 expression (SCL16A1) however, was
significantly elevated in HPV−ve tumours (p= 0.012), suggesting
a potential tumour subtype-specific, metabolic target (Fig. 5a).
Analysis of the TCGA HNSCC dataset (n= 279)31 confirmed higher
expression of MCT1 in HPV-ve tumour samples (Fig. 5b). Immu-
nochemistry analysis of MCT1 expression in a large cohort of
HNSCC patients (HPV−ve n= 100; HPV+ve n= 131)23 also showed
significantly stronger MCT1 expression in HPV-ve tumours (Fig. 5c;
p < 0.0001; Mann-Whitney U test), correlating weakly with Glut1
expression (Spearman’s Rho= 0.228 p= 0.001) and tumour
PAPER
Baschnagel et al. 2015
Baschnagel et al. 2015
45 17.3 52 16.3
10.3
11.3
13.25
17.5
9.1
8.57
5.13
19
25
30
28
17
25
13.7
11.7
11.95
17.7
9.72
13.53
6.43
n/k n/k
7
18
49
50
28
98
Clark et al. 2015
Fleming et al. 2018*
Fleming et al. 2018
Garsa et al. 2013
Garsa et al. 2013
Huang et al. 2015
Joo et al. 2014
Joo et al. 2014
Schouten et al. 2014
Schouten et al. 2014
Total (95% CI)
Tahari et al. 2014
Study Mean
[SUV(max)]
17.3 6.86
9.59
6.97
4.55
5.98
45 16.3
11.3
13.25
9.1
8.57
7.36
5.14
5.13
4.61
7.08 52
19
25
50
28
7
18
28
17
115
Mean difference
IV, fixed, 95% CI [SUV(max)]
–10 –5
HPV–ve HPV+ve
0 5 10
Heterogeneity. Chi2 = 6.93, df = 4 (P = 1.14); I2 = 42%
Test for overall effect. Z = 1.71 (P = 0.09)
174 100.00% 1.22 [–0.18, 2.62]
11.7
11.95
9.72
13.53
SD
[SUV(max)]
HPV–ve HPV+ve Mean difference
Total Mean[SUV(max)]
SD
[SUV(max)] Total
Weight IV, fixed, 95% CI
[SUV(max)]
24.30% 1.00 [–1.78, 3.78]
0.40 [–7.44, 8.24]
–1.30 [–5.10, 2.50]
0.62 [–1.59, 2.83]
4.96 [1.64, 8.28]
3.20%
13.50%
40.20%
17.80%
HPV–ve
Sample size Sample sizeSUV(max) SUV(max)
HPV+ve
a
b
Fig. 4 Comparison of combined FDG-PET derived SUV(max) scores for HPV−ve and HPV+ve tumours from a meta-analysis of the available
literature (1946–present). a Table of collated mean SUV(max) scores alongside sample numbers for all relevant studies (*= current study).
Where mean SUV(max) was not reported, indicated mean values (italics) were estimated from reported median, range and sample size25 (n/k
not known). b Table and Forest plot of comparison of SUV(max) for HPV−ve vs HPV+ve patients (mean difference, fixed effect analysis).
Difference in means was +1.22 (−0.18–2.62 [95% CI]), indicating a strong trend for higher SUV(max) scores in HPV−ve disease although no
overall significance difference was proven
HPV, tumour metabolism and novel target identification in head and neck. . .
JC Fleming et al.
362
cohesion (pattern of invasion; Spearman’s Rho= 0.232 p= 0.001),
but not with tumour grade, perineural, lymphatic or vascular
spread. (Supplementary Figure 8a–c). MCT1 expression was
negatively associated with disease-specific survival in all orophar-
yngeal HNSCC (Fig. 5d, upper panel; log-rank= 0.001;), but
showed only a non-significant trend when subcategorised
according to HPV status, more apparent in HPV-ve tumours (Fig. 5d,
middle panel, log-rank= 0.155; HPV+ve HNSCC, Supplementary
Figure 8d, left panel, log-rank= 0.706). Notably however, treat-
ment sub-group survival analysis in HPV−ve tumours showed
that MCT1 expression had a significant negative association
with survival in patients treated with primary (chemo)radio-
therapy (Fig. 5e; log-rank= 0.05) compared with those treated
surgically (Supplementary Figure 8d, right panel, log-rank= 0.668).
Sensitivity of HNSCC cell lines to AZD3965, a novel MCT1 inhibitor
Targeting lactate balance has previously been suggested as a
potential therapeutic option to target cancer cells.30 We therefore
tested the effect of inhibiting MCT1 on HNSCC cell function
in vitro, using AZD3965 (AstraZeneca, Waltham, MA), a selective
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inhibitor of MCT1,15 which is in early-phase clinical testing. We first
confirmed MCT1 expression in a panel of HPV-ve (SCC-25, Detroit
562) and HPV+ve (UD-SCC-2 and UPCI:SCC90) cell lines (Fig. 6a).
Given the correlation between MCT1 and tumour cohesion in the
OPSCC patient cohort, we initially tested the effect of AZD3965 on
cell invasion in Transwell invasion assays; only invasion of HPV−ve
cells was significantly reduced by MCT1 inhibition (Fig. 6b; p <
0.0001 and p < 0.05, SCC-25 and Detroit 562 respectively). Since
highest expression of MCT1 was seen in SCC-25 cells, we analysed
the effect of AZD3965 in more detail, using this cell line as
representative of our target population of HPV−ve HNSCC. Initially
we performed extracellular flux analysis to analyse real-time
metabolic outputs, following MCT1 inhibition. AZD3965 produced
a dose-dependent reduction of glycolytic rate as well as glycolytic
capacity (Fig. 6c). This was mirrored by an increase in mitochon-
drial respiration (Supplementary Figure 9). Organotypic assays
were used to study invasion in a more physiological context, and
similar to Transwell assays, showed a reduction following
AZD3965 treatment (p < 0.01; Fig. 6d). In clonogenic survival
assays, inhibition of MCT1 activity resulted in an approximately
50% reduction in colony survival and intensity (incorporating cell
number) (Fig. 6e; P < 0.0001). Since the negative survival impact of
MCT1 expression was most evident in patients treated with
chemoradiotherapy, we hypothesised that AZD3965 may make
SCC-25 cells more radiosensitive. SCC-25 cells were treated
with AZD3965 for 48 h, and then exposed to incremental γ-rays
doses up to a maximum of 6-Gy. AZD3965-treated cells
were significantly more sensitive to irradiation (Fig. 6f; p=
0.0312).
DISCUSSION
HNSCC has high rates of glucose uptake,32 and FDG uptake in PET
imaging reflects this,33 however, it is not clear whether metabolic
differences exist between HPV+ve and HPV-ve HNSCC, tumour
subgroups that show very different clinical behaviours. We found
that HPV−ve tumours have a more glycolytic phenotype compared
to their HPV+ve counterparts, but also have a globally altered
metabolic profile consistent with the greater requirements for
macromolecule production, as well as alterations in other
metabolic and biosynthetic pathways. In keeping with recent
advances in diverse metabolic targeting (reviewed by Luengo
et al.34), RNA sequencing data showed enrichment in HPV−ve
tumours of additional metabolic pathways including those
involved in fatty acid, lipid and nucleotide biosynthesis. Under-
standing the wider metabolic features of HPV−ve tumours, and
how this may affect response to treatment may enable us to
develop treatment combinations that exploit metabolic
dependence.
Findings of increased expression of glycolytic genes in HPV−ve
tumours were supported by extracellular flux analysis confirming
a higher rate of glycolysis and glycolytic capacity in HPV−ve cell
lines, in keeping with the requirement for redox balance in the
presence of rapid cell division. It may also explain why HPV−ve cell
lines showed a greater glycolytic capacity in vitro, with their full
glycolytic potential moderated by elevated PKM2 to allow for
intermediate shuttling for nucleotide and NADPH production. Our
finding of concurrent higher oxygen consumption rates in HPV-ve
cell lines is consistent with other studies noting that mitochondrial
function is not impaired in the majority of cancer cells.35,36 The
reason for differences in glycolysis between HPV−ve and HPV+ve
HNSCC is uncertain; the three rate limiting reactions in glycolysis
are catalysed by hexokinase, phosphofructokinase and pyruvate
kinase, and all are relatively upregulated in HPV−ve HNSCC. Recent
studies show that TP53, a negative regulator of glycolysis, is
mutated in around 75–85% of HPV-ve HNSCC.31,37–39
Hypoxia inducible factor 1 alpha (HIF1a) is also a potent
promoter of glycolysis which is commonly expressed in HNSCC,
being positively regulated by hypoxia and other factors including
oncogenic signalling and reactive oxygen species.40
Ultimately the classification of metabolic phenotype in HNSCC
may have important relevance in understanding the biology and
clinical behaviour of the disease subgroups, indicating that
glycolytic HPV−ve tumours have a biosynthetic advantage over
their HPV+ve counterparts.41,42 Altered tumour metabolism may
also provide opportunities for therapeutic targeting of specific
metabolism-related pathways. MCT1 expression is differentially
upregulated in HPV−ve tumours and significantly associated with
poor survival in OPSCC patients, notably in those with HPV−ve
disease treated with chemoradiotherapy. Similar correlation of
MCT1 expression with poor prognosis has been reported in
tumours of the breast,43 ovary,44 stomach45 and colon.46 Func-
tional flux analysis of response to MCT1 inhibition indicated a shift
in the metabolism profile of HNSCC cell lines from glycolysis to
oxidative phosphorylation, resulting in suppressed tumour inva-
sion and colony formation. Although previously considered a
lactate importer, MCT1 has demonstrated bi-directionality47 which
may help to explain the variable effects on cell metabolism
produced by MCT1 inhibition reported in the literature. For
example, in various cancer cell lines Bola et al.48 demonstrated
that AZD3965 resulted in an increase in glycolysis and glycolytic
enzymes whereas, similar to the present study, Doherty et al.49
found that MCT1 inhibition rapidly abrogated glycolytic function.
The presumed reduction in intracellular pH following reduction of
lactate efflux measured helps explain the negative cell survival
effects on HNSCC cell lines following MCT1 inhibition observed in
clonogenic assays. Areas of low pH in the tumour microenviron-
ment have been demonstrated to correspond with cancer cell
migration and invasion,50,51 therefore the reduction in lactate
efflux with the MCT1 inhibitor may also explain the functional
effects on cell migration and invasion. However, while these data
suggest that MCT1 targeted therapy could be of potential benefit
to patients with HPV−ve tumours, further pre-clinical modelling is
required to translate these finding.
FDG-PET is now a standard-of-care investigation in the
diagnosis of primary and metastatic HNSCC, as well as being
used for post-treatment surveillance. We found that SUV(max)
alone cannot distinguish HPV status in primary tumours, especially
Fig. 5 In vivo expression and clinical significance of MCT1 in HNSCC. a Analysis of RNA sequencing data for expression of MCT1 (gene
SLC16A1), MCT2 (SLC16A7) and MCT4 (SLC16A3) in HPV+ve (n= 11) vs HPV−ve (n= 25) HNSCC. CDKN2A (p16INK4a) is included as validation for
HPV positivity corroborating immunochemistry. Read counts compared with non-parametric Mann–Whitney test following graphical
confirmation of non-normalised data distribution. Significantly increased expression levels in HPV-ve tumours are observed for MCT1 (p=
0.0012). b TCGA HNSCC dataset (n= 279; 243 HPV−ve, 36 HPV+ve) was interrogated for MCT1 (SLC16A1) RNA expression and log2 values are
plotted against viral status, confirming increased expression in HPV−ve tumours (p < 0.0001). c Representative immunohistochemical staining
showing examples of MCT1 expression levels in HPV-ve and HPV+ve HNSCC. Scale bar= 100 microns. MCT1 expression overall was
significantly higher in HPV−ve tumours (Chi-squared, χ2 < 0.0001). d Kaplan-Meier disease-specific survival curves for all oropharyngeal SCC
(OPSCC; top) and HPV−ve OPSCC (middle) based on MCT1 expression scored on immunohistochemistry as low (absent/weak) or high
(moderate/high). A significant correlation was evident between MCT1 expression and disease specific survival in OPSCC (log-rank= 0.001).
e Kaplan–Meier in HPV−ve patients treated with (chemo)radiation as primary modality demonstrating significant disease specific survival
association in this cohort (log-rank= 0.05). Patients receiving neoadjuvant treatment, post-operative radiotherapy only or palliative doses
were excluded. ns not significant, *p ≤ 0.05 and ****p < 0.0001
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given the range of reported metrics and variability of imaging
parameters between centres. Standardised uptake value (SUV)
measurements have been shown to be reproducible and have
both diagnostic and prognostic value in HNSCC52 but with these
imaging metrics alone, there have been conflicting reports in the
literature about the significance of HPV status to glycolytic
phenotype.52,53 It is possible that dynamic PET imaging over time
could pick up differences in the rate of glucose uptake between
HPV-ve and HPV+ve tumours. However, imaging at a single, static
and relatively late time point, as currently occurs in clinical
imaging protocols, does not distinguish between tumour
subgroups.
In summary, we show that there are significant metabolic
differences between HPV−ve and HPV+ve HNSCC; whilst this does
not impact on the ability to clinically detect these subgroups using
PET imaging, our data adds to the growing evidence that
targeting glycolytic pathways may have therapeutic value in
HPV−ve disease.
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